Demographics of randomised patients according to treatment arm, 18–24 months after diagnosis
| Variable | Continuation group (n=59) | Withdrawal group (n=51) | p Value |
| Age (years) | 57.7±14.1 | 57.4±14.3 | 0.89 |
| Sex (%) | 0.69 | ||
| Male | 49 | 53 | |
| Female | 51 | 47 | |
| AAV type (%) | 0.96 | ||
| GPA | 47 | 47 | |
| MPA | 53 | 53 | |
| ANCA at diagnosis (%) | 0.11 | ||
| PR3 | 46 | 59 | |
| MPO | 47 | 41 | |
| Negative | 7 | 0 | |
| Delay from diagnosis (months) | 18.6±0.2 | 19.0±0.2 | 0.28 |
| Serum creatinine (μmol/L) | 140±67 | 129±54 | 0.34 |
| eGFR (mL/min/1.73 m2) | 51.6±23.0 | 55.8±23.4 | 0.34 |
| ANCA | 0.59 | ||
| Positive | 51% | 56% | |
| Negative | 49% | 44% | |
| Prednisolone dose (mg/day) | 5.8±2.3 | 5.9±2.1 | 0.61 |
| Azathioprine dose (mg/day) | 102±35 | 95±39 | 0.27 |
| VDI | 1.8±0.2 | 1.8±0.2 | 0.98 |
Values are given as mean±SD.
AAV, ANCA-associated vasculitis; eGFR, estimated glomerular filtration rate; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; PR3, proteinase 3; MPO, myeloperoxidase; VDI, Vasculitis Damage Index.